ASBMR President Discusses Improving Drug Development Pipeline in Lancet Podcast
Date: November 24, 2015
In the latest Lancet Blog Post, ASBMR President Douglas P. Kiel, M.D., M.P.H. discusses changes that are being advocated to overhaul the process and requirements for osteoporosis clinical trials. This discussion follows the recent testimony that Dr. Kiel provided at the FDA Scientific Workshop: Osteoporosis Drug Development – Moving Forward. Read more about that here.
The podcast, No Bones About It, discusses the substantial advances in bone biology and the identification of biomarkers as a promising area for improving the drug development pipeline.
To listen to Dr. Kiel’s 20 minute podcast, click here.